vs
Amphastar Pharmaceuticals, Inc.（AMPH）与PROGRESS SOFTWARE CORP（PRGS）财务数据对比。点击上方公司名可切换其他公司
PROGRESS SOFTWARE CORP的季度营收约是Amphastar Pharmaceuticals, Inc.的1.4倍（$252.7M vs $183.1M），Amphastar Pharmaceuticals, Inc.净利率更高（13.3% vs 10.2%，领先3.2%），PROGRESS SOFTWARE CORP同比增速更快（17.5% vs -1.8%），PROGRESS SOFTWARE CORP自由现金流更多（$59.9M vs $24.6M），过去两年PROGRESS SOFTWARE CORP的营收复合增速更高（17.0% vs 3.2%）
安福斯制药是一家上市的美国特种制药企业，公司成立于2004年5月，核心业务为吸入制剂及鼻腔给药产品的研发、生产与销售，聚焦特色医药领域深耕发展。
Progress Software是全球领先的企业级软件服务商，主营应用开发平台、数据连接工具、数字体验解决方案等产品，服务覆盖金融、医疗、制造、零售等多行业的全球企业客户，助力客户搭建高性能可扩展的业务应用，提升运营效率。
AMPH vs PRGS — 直观对比
营收规模更大
PRGS
是对方的1.4倍
$183.1M
营收增速更快
PRGS
高出19.4%
-1.8%
净利率更高
AMPH
高出3.2%
10.2%
自由现金流更多
PRGS
多$35.3M
$24.6M
两年增速更快
PRGS
近两年复合增速
3.2%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $183.1M | $252.7M |
| 净利润 | $24.4M | $25.7M |
| 毛利率 | 46.8% | 81.6% |
| 营业利润率 | 19.4% | 15.2% |
| 净利率 | 13.3% | 10.2% |
| 营收同比 | -1.8% | 17.5% |
| 净利润同比 | -35.7% | 2144.6% |
| 每股收益（稀释后） | $0.51 | $0.59 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AMPHPRGS
| Q4 25 | $183.1M | $252.7M | ||
| Q3 25 | $191.8M | $249.8M | ||
| Q2 25 | $174.4M | $237.4M | ||
| Q1 25 | $170.5M | $238.0M | ||
| Q4 24 | $186.5M | $215.0M | ||
| Q3 24 | $191.2M | $178.7M | ||
| Q2 24 | $182.4M | $175.1M | ||
| Q1 24 | $171.8M | $184.7M |
净利润AMPHPRGS
| Q4 25 | $24.4M | $25.7M | ||
| Q3 25 | $17.4M | $19.4M | ||
| Q2 25 | $31.0M | $17.0M | ||
| Q1 25 | $25.3M | $10.9M | ||
| Q4 24 | $38.0M | $1.1M | ||
| Q3 24 | $40.4M | $28.5M | ||
| Q2 24 | $37.9M | $16.2M | ||
| Q1 24 | $43.2M | $22.6M |
毛利率AMPHPRGS
| Q4 25 | 46.8% | 81.6% | ||
| Q3 25 | 51.4% | 81.0% | ||
| Q2 25 | 49.6% | 80.1% | ||
| Q1 25 | 50.0% | 80.6% | ||
| Q4 24 | 46.5% | 83.0% | ||
| Q3 24 | 53.3% | 83.7% | ||
| Q2 24 | 52.2% | 81.7% | ||
| Q1 24 | 52.4% | 82.2% |
营业利润率AMPHPRGS
| Q4 25 | 19.4% | 15.2% | ||
| Q3 25 | 13.2% | 17.6% | ||
| Q2 25 | 24.2% | 16.3% | ||
| Q1 25 | 21.9% | 13.6% | ||
| Q4 24 | 24.2% | 10.0% | ||
| Q3 24 | 29.8% | 22.6% | ||
| Q2 24 | 30.3% | 15.5% | ||
| Q1 24 | 27.9% | 19.0% |
净利率AMPHPRGS
| Q4 25 | 13.3% | 10.2% | ||
| Q3 25 | 9.0% | 7.8% | ||
| Q2 25 | 17.8% | 7.2% | ||
| Q1 25 | 14.8% | 4.6% | ||
| Q4 24 | 20.4% | 0.5% | ||
| Q3 24 | 21.1% | 15.9% | ||
| Q2 24 | 20.8% | 9.2% | ||
| Q1 24 | 25.1% | 12.3% |
每股收益（稀释后）AMPHPRGS
| Q4 25 | $0.51 | $0.59 | ||
| Q3 25 | $0.37 | $0.44 | ||
| Q2 25 | $0.64 | $0.39 | ||
| Q1 25 | $0.51 | $0.24 | ||
| Q4 24 | $0.74 | $0.01 | ||
| Q3 24 | $0.78 | $0.65 | ||
| Q2 24 | $0.73 | $0.37 | ||
| Q1 24 | $0.81 | $0.51 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $282.8M | $94.8M |
| 总债务越低越好 | $608.7M | $1.4B |
| 股东权益账面价值 | $788.8M | $478.3M |
| 总资产 | $1.6B | $2.5B |
| 负债/权益比越低杠杆越低 | 0.77× | 2.93× |
8季度趋势，按日历期对齐
现金及短期投资AMPHPRGS
| Q4 25 | $282.8M | $94.8M | ||
| Q3 25 | $276.2M | $99.0M | ||
| Q2 25 | $231.8M | $102.0M | ||
| Q1 25 | $236.9M | $124.2M | ||
| Q4 24 | $221.6M | $118.1M | ||
| Q3 24 | $250.5M | $232.7M | ||
| Q2 24 | $217.8M | $190.4M | ||
| Q1 24 | $289.6M | $133.2M |
总债务AMPHPRGS
| Q4 25 | $608.7M | $1.4B | ||
| Q3 25 | $608.6M | $1.4B | ||
| Q2 25 | $607.7M | $1.5B | ||
| Q1 25 | $603.9M | $1.5B | ||
| Q4 24 | $601.6M | $1.5B | ||
| Q3 24 | $596.4M | — | ||
| Q2 24 | $586.9M | — | ||
| Q1 24 | $594.0M | — |
股东权益AMPHPRGS
| Q4 25 | $788.8M | $478.3M | ||
| Q3 25 | $776.7M | $477.7M | ||
| Q2 25 | $757.5M | $452.7M | ||
| Q1 25 | $751.3M | $431.8M | ||
| Q4 24 | $732.3M | $438.8M | ||
| Q3 24 | $727.7M | $425.6M | ||
| Q2 24 | $713.3M | $401.7M | ||
| Q1 24 | $672.4M | $461.7M |
总资产AMPHPRGS
| Q4 25 | $1.6B | $2.5B | ||
| Q3 25 | $1.7B | $2.4B | ||
| Q2 25 | $1.6B | $2.4B | ||
| Q1 25 | $1.6B | $2.5B | ||
| Q4 24 | $1.6B | $2.5B | ||
| Q3 24 | $1.5B | $1.6B | ||
| Q2 24 | $1.5B | $1.6B | ||
| Q1 24 | $1.6B | $1.5B |
负债/权益比AMPHPRGS
| Q4 25 | 0.77× | 2.93× | ||
| Q3 25 | 0.78× | 2.97× | ||
| Q2 25 | 0.80× | 3.22× | ||
| Q1 25 | 0.80× | 3.50× | ||
| Q4 24 | 0.82× | 3.48× | ||
| Q3 24 | 0.82× | — | ||
| Q2 24 | 0.82× | — | ||
| Q1 24 | 0.88× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $32.9M | $62.8M |
| 自由现金流经营现金流 - 资本支出 | $24.6M | $59.9M |
| 自由现金流率自由现金流/营收 | 13.4% | 23.7% |
| 资本支出强度资本支出/营收 | 4.5% | 1.1% |
| 现金转化率经营现金流/净利润 | 1.35× | 2.44× |
| 过去12个月自由现金流最近4个季度 | $121.2M | $229.5M |
8季度趋势，按日历期对齐
经营现金流AMPHPRGS
| Q4 25 | $32.9M | $62.8M | ||
| Q3 25 | $52.6M | $73.4M | ||
| Q2 25 | $35.6M | $30.0M | ||
| Q1 25 | $35.1M | $68.9M | ||
| Q4 24 | $29.0M | $19.7M | ||
| Q3 24 | $60.0M | $57.7M | ||
| Q2 24 | $69.1M | $63.7M | ||
| Q1 24 | $55.3M | $70.5M |
自由现金流AMPHPRGS
| Q4 25 | $24.6M | $59.9M | ||
| Q3 25 | $47.2M | $72.4M | ||
| Q2 25 | $25.0M | $29.5M | ||
| Q1 25 | $24.4M | $67.7M | ||
| Q4 24 | $16.6M | $16.8M | ||
| Q3 24 | $46.2M | $56.6M | ||
| Q2 24 | $63.1M | $62.7M | ||
| Q1 24 | $46.5M | $70.2M |
自由现金流率AMPHPRGS
| Q4 25 | 13.4% | 23.7% | ||
| Q3 25 | 24.6% | 29.0% | ||
| Q2 25 | 14.3% | 12.4% | ||
| Q1 25 | 14.3% | 28.4% | ||
| Q4 24 | 8.9% | 7.8% | ||
| Q3 24 | 24.1% | 31.7% | ||
| Q2 24 | 34.6% | 35.8% | ||
| Q1 24 | 27.1% | 38.0% |
资本支出强度AMPHPRGS
| Q4 25 | 4.5% | 1.1% | ||
| Q3 25 | 2.8% | 0.4% | ||
| Q2 25 | 6.1% | 0.2% | ||
| Q1 25 | 6.3% | 0.5% | ||
| Q4 24 | 6.7% | 1.3% | ||
| Q3 24 | 7.2% | 0.6% | ||
| Q2 24 | 3.3% | 0.5% | ||
| Q1 24 | 5.1% | 0.2% |
现金转化率AMPHPRGS
| Q4 25 | 1.35× | 2.44× | ||
| Q3 25 | 3.03× | 3.78× | ||
| Q2 25 | 1.15× | 1.76× | ||
| Q1 25 | 1.39× | 6.30× | ||
| Q4 24 | 0.76× | 17.13× | ||
| Q3 24 | 1.48× | 2.03× | ||
| Q2 24 | 1.82× | 3.93× | ||
| Q1 24 | 1.28× | 3.11× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AMPH
| Other Products | $62.4M | 34% |
| Baqsimi | $46.7M | 26% |
| Primatenemist | $27.9M | 15% |
| Epinephrine | $17.1M | 9% |
| Lidocaine | $14.9M | 8% |
| Glucagon | $14.1M | 8% |
PRGS
| Maintenanceand Services | $187.5M | 74% |
| Share File Acquisition | $67.5M | 27% |
